Skip to main content
Premium Trial:

Request an Annual Quote

AnPac Bio-Medical Inks $15M Equity Investment Deal

NEW YORK — AnPac Bio-Medical Science said on Monday that it has signed an investment agreement that will raise $15 million over the next two and a half years.

Under the terms of the deal, Hunan Weitou Technology has agreed to invest $3 million in AnPac every six months for 30 months, with the first investment comprising the purchase of AnPac stock at $.414 per share.

The initial investment is expected to occur before the end of this month, Shanghai-based AnPac said. Additional details of the arrangement were not disclosed.

In March, AnPac — which performs cancer screening and detection tests from CLIA labs in China and the US — said that its shares would be delisted from the Nasdaq for failure to meet a number of the stock exchange's listing requirements.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.